• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NeoStem finalizes name change to Caladrius Biosciences

NeoStem finalizes name change to Caladrius Biosciences

June 25, 2015
CenterWatch Staff

Caladrius Biosciences, a cell therapy company with a late-stage clinical program for immuno-oncology, has finalized its corporate name change from NeoStem to Caladrius.

“Coming on the heels of the recent $17.7 million grant awarded to us from the California Institute for Regenerative Medicine in support of our currently enrolling phase III trial studying CLBS20, also known as NBS20, as a therapy for metastatic melanoma, our new identity as Caladrius Biosciences reflects our position as a leader in the innovation, development and manufacture of cell-based individualized medicine,” said Dr. David J. Mazzo, CEO of Caladrius.

Progenitor Cell Therapy, a wholly-owned subsidiary of Caladrius and a single source cell therapy service provider, has been renamed PCT, a Caladrius company, also effective immediately, with no change to its focus on process development, engineering and manufacturing for clients across the cell therapy industry.

The product candidates in the company’s therapeutic pipeline will be referred to under new names.

  • CLBS20, also known as NBS20, the company’s lead product candidate, currently enrolling in the Intus phase III trial for the treatment of metastatic melanoma;
  • CLBS10, formerly NBS10, an ischemic repair treatment of damaged heart muscle after acute myocardial infarction in late phase II; and
  • CLBS03, formerly NBS03D, which is poised to enter phase II in a study for the preservation of beta cell function in adolescents with type 1 diabetes.

In Roman mythology, the Caladrius is a bird that visits the ill and is said to be able to absorb patients’ illnesses and fly away, dispersing the illness and healing both itself and the patient. In that same spirit of recovery, Caladrius Biosciences is committed to its mission of bringing new, innovative and treatment paradigm-changing medical therapies to market, and in so doing, improving patients’ lives and creating value for its shareholders.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing